Table 1.
Clinico-pathological features of 431 patients with a preoperative histopathologic diagnosis of DCIS
| DCIS (N = 397) | Invasive component (N = 34) | p | |
|---|---|---|---|
| Age (yrs) | 50.2 ± 10.6 | 50.3 ± 11.4 | 0.967 |
| US tumor size (mm, mean ± SD) | 0.663 | ||
| ≤ 2 cm | 251 (63.2%) | 19 (55.9%) | |
| > 2 cm | 133 (33.5%) | 14 (41.2%) | |
| Not seen | 13 (3.3%) | 1 (2.9%) | |
| US finding | 0.567 | ||
| Non-mass | 42 (10.6%) | 2 (5.9%) | |
| Mass | 355 (89.4%) | 32 (94.1%) | |
| Mammographic finding | 0.286 | ||
| Asymmetry | 25 (6.3%) | 2 (5.9%) | |
| Microcalcification | 292 (73.6%) | 21 (61.8%) | |
| Architecture distorsion | 8 (2.0%) | 2 (5.9%) | |
| No specific finding | 72 (18.1%) | 9 (26.5%) | |
| Biopsy methods | 0.001 | ||
| Needle Biopsy | 250 (63.0%) | 32 (94.1%) | |
| Excisional Biopsy | 147 (37.0%) | 2 (5.9%) | |
| Surgery type | 0.009 | ||
| Breast conserving surgery | 204 (51.4%) | 9 (26.5%) | |
| Total mastectomy | 193 (48.6%) | 25 (73.5%) | |
| Pathologic DCIS size | 0.010 | ||
| ≤ 2 cm | 241 (60.7%) | 12 (35.3%) | |
| > 2 cm | 148 (37.3%) | 20 (58.8%) | |
| No residual DCIS | 8 (2.0%) | 2 (5.9%) | |
| Invasive tumor size (mm, mean ± SD) | 7.0 ± 8.9 | < 0.001 | |
| pN | 0.117 | ||
| 0 | 393 (99.0%) | 32 (94.1%) | |
| 1 | 4 (1.0%) | 2 (5.9%) | |
| Multifocality | 1.000 | ||
| Absent | 313 (78.8%) | 27 (79.4%) | |
| Present | 84 (21.2%) | 7 (20.6%) | |
| Nuclear grade | 0.125 | ||
| Low/intermediate | 319 (80.4%) | 23 (67.6%) | |
| High | 78 (19.6%) | 11 (32.4%) | |
| Estrogen receptor | 0.177 | ||
| - | 88 (22.2%) | 12 (35.3%) | |
| + | 302 (76.1%) | 22 (64.7%) | |
| Unknown | 7 (1.8%) | 0 (0%) | |
| Progesterone receptor | 0.130 | ||
| - | 123 (31.0%) | 16 (47.1%) | |
| + | 267 (7.3%) | 18 (52.9%) | |
| Unknown | 7 (1.8%) | 0 (0%) | |
| HER2 | 0.679 | ||
| - | 241 (61.2%) | 20 (58.8%) | |
| Overexpression | 147 (37.0%) | 14 (41.2%) | |
| Unknown | 7 (1.8%) | 0 (0%) | |
| Ki-67(%) | 8.8 ± 9.1 | 15.3 ± 25.5 | 0.271 |
| Closest margin (mm) | 4.8 ± 5.2 | 5.1 ± 4.3 | 0.788 |
| Follow up periods (months) | 46.0 ± 35.2 | 61.6 ± 46.5 | 0.064 |
| Any recurrence | 1.000 | ||
| Absent | 389 (98.0%) | 33 (97.1%) | |
| Present | 8 (2.0%) | 1 (2.9%) | |
| Chemotherapy | < 0.001 | ||
| no | 381 (96.0%) | 18 (52.9%) | |
| yes | 16 (4.0%) | 16 (47.1%) | |
| Hormone therapy | 0.147 | ||
| no | 90 (22.7%) | 12 (35.3%) | |
| yes | 307 (77.3%) | 22 (64.7%) |
Data are expressed as means±standard deviations or n (%)
Abbreviations: DCIS Ductal carcinoma in situ, US Ultrasonography, HER2 Human epidermal growth factor receptor 2